Jeanine Ballard

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.2kcitations43works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ion channel regulation and function(11), Pharmacogenetics and Drug Metabolism(6), Neuroscience and Neuropharmacology Research(5), HIV Research and Treatment(4), Drug Transport and Resistance Mechanisms(4)

Publications43 total

Correction to “Large-Scale Compartmental Model-Based Study of Preclinical Pharmacokinetic Data and Its Impact on Compound Triaging in Drug Discovery”
Molecular Pharmaceutics·2026
Elucidation of Mechanism of Action in Drug Invention: Using Stable Isotope Tracers to Unravel Biochemical Kinetics
Pharmacology Research & Perspectives·2025· 2 citedOpen Access
Large-Scale Compartmental Model-Based Study of Preclinical Pharmacokinetic Data and Its Impact on Compound Triaging in Drug Discovery
Molecular Pharmaceutics·2025· 1 cited
Delivery of Islatravir via High Drug‐Load, Long‐acting Microarray Patches for the Prevention or Treatment of Human Immunodeficiency Virus
Advanced Healthcare Materials·2025· 1 citedOpen Access
Quantifying protein kinetics in vivo: influence of precursor dynamics on product labeling
American Journal of Physiology-Endocrinology and Metabolism·2024Open Access
Large scale compartmental model-based study of preclinical pharmacokinetic data and its impact on compound triaging in drug discovery
2024Open Access
Large scale compartmental model-based study of preclinical pharmacokinetic data and its impact on compound triaging in drug discovery
2024Open Access
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> Inhibitor
Journal of Medicinal Chemistry·2024· 31 cited
Abstract B074: Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor
Molecular Cancer Therapeutics·2023· 1 cited
A Retrospective Analysis of Preclinical and Clinical Pharmacokinetics from Administration of Long-Acting Aqueous Suspensions
Pharmaceutical Research·2023· 9 cited
Physiologically-based modeling of cholate disposition in beagle dog with and without treatment of the liver transporter inhibitor simeprevir
Computational Toxicology·2022· 1 citedOpen Access
Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose
Frontiers in Pharmacology·2021· 7 citedOpen Access
Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Na<sub>v</sub>1.7 for the Treatment of Pain
Journal of Medicinal Chemistry·2021· 21 citedOpen Access
Guiding Chemically Synthesized Peptide Drug Lead Optimization by Derisking Mast Cell Degranulation-Related Toxicities of a NaV1.7 Peptide Inhibitor
Toxicological Sciences·2021· 5 cited
Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors
ACS Medicinal Chemistry Letters·2021· 9 citedOpen Access
Discovery of Arylsulfonamide Na <sub>v</sub> 1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile
ACS Medicinal Chemistry Letters·2021· 12 citedOpen Access
Na <sub>v</sub> 1.7 target modulation and efficacy can be measured in nonhuman primate assays
Science Translational Medicine·2021· 20 cited
In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform
SLAS DISCOVERY·2021· 6 citedOpen Access
Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate
Pharmaceutical Research·2020· 5 citedOpen Access
Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors
SLAS DISCOVERY·2020· 28 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Richard L. Kraus(17), Cuyue Tang(13), Victor N. Uebele(12), Thomayant Prueksaritanont(11), Christopher R. Gibson(11), James C. Barrow(11), Cindy E. Nuss(11), Scott M. Doran(11), Kenneth E. Rittle(9), George D. Hartman(9), John J. Renger(9), Susan L. Garson(9), Yuxing Li(9), Thomas S. Reger(9), Yuhsin Kuo(8), Zhi-Qiang Yang(6), Youheng Shu(6), Steven V. Fox(5), Michael J. Marino(5), Valerie Kuzmick Graufelds(5)